Effectiveness of Tai Chi vs Cognitive Behavioural Therapy for Insomnia in Middle-Aged and Older Adults
November 27, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Background
Phenylketonuria (PKU) is a rare genetic disorder affecting the metabolism of phenylalanine, an amino acid. Proteins are made up of amino acids, and phenylalanine is derived from diet—especially from foods high in protein.
It is caused by a mutation in the gene that provides instructions for making an enzyme called phenylalanine hydroxylase (PAH). This enzyme is crucial for breaking down phenylalanine into another amino acid called tyrosine. In individuals with PKU, the lack or deficiency of functional PAH leads to the accumulation of phenylalanine in the blood and body tissues.
High levels of phenylalanine can be toxic to the developing brain, especially in infants and young children. If left untreated, PKU can result in intellectual disabilities, seizures, behavioral problems, and other neurological issues.
PKU is typically diagnosed through newborn screening, which involves a blood test shortly after birth. Early detection is crucial for initiating treatment before the toxic effects of phenylalanine can cause irreversible damage.
The primary treatment for PKU involves a strict, lifelong low-phenylalanine diet. This means restricting the intake of high-protein foods, such as meat, dairy products, and certain grains. Additionally, individuals with PKU may take a special formula that provides the necessary nutrients while limiting phenylalanine. Regular monitoring of blood phenylalanine levels is essential to adjust the diet and treatment plan as needed.
Epidemiology
Prevalence: PKU occurs worldwide but is more commonly observed in certain ethnic groups. The prevalence of PKU varies among different populations and regions. In the United States, for example, PKU occurs in about 1 in 10,000 to 15,000 births.
Genetic Inheritance: PKU is a genetic disorder that is autosomal recessive. This implies that for a child to be impacted, both parents need to have a copy of the defective gene. Every pregnancy increases the likelihood that a child of carriers will have PKU by 25%.
Ethnic Variations: The prevalence of PKU can vary among ethnic groups. It is more commonly seen in individuals of European, Native American, and Turkish descent, while it is less common in individuals of African, Hispanic, and Asian descent.
Newborn Screening: Many countries have implemented newborn screening programs to detect PKU early in life. Newborn screening involves a blood test shortly after birth to measure the levels of phenylalanine. It is essential to identify and treat neurological problems early on in order to avoid their development.
International Variances: PKU prevalence can vary significantly between countries. Some countries have established comprehensive newborn screening programs and effective treatment protocols, leading to better outcomes for individuals with PKU. In contrast, in regions with limited access to healthcare and newborn screening, cases may go undetected and untreated.
Gender Distribution: PKU affects both males and females, and there is generally no significant gender bias in its occurrence.
Anatomy
Pathophysiology
Genetic Mutation: Mutations in the PAH gene on chromosome 12 result in PKU, an autosomal recessive genetic disorder. Individuals with PKU inherit two mutated copies of the gene, one from each parent. These mutations result in the production of a defective or insufficient amount of PAH.
PAH Enzyme Deficiency: PAH is an enzyme responsible for converting phenylalanine into another amino acid called tyrosine. In individuals with PKU, the deficiency or absence of functional PAH leads to the impaired conversion of phenylalanine.
Accumulation of Phenylalanine: Due to the lack of PAH activity, phenylalanine accumulates in the blood and body tissues. Elevated levels of phenylalanine in the bloodstream are toxic to the developing brain, particularly in infants and young children.
Crossing the Blood-Brain Barrier: Unlike tyrosine, phenylalanine has difficulty crossing the blood-brain barrier. However, when phenylalanine levels are excessively high in the blood, it can enter the brain, leading to neurological damage.
Impact on Brain Development: The brain’s normal development and function may be hampered by phenylalanine buildup. This can result in intellectual disabilities, seizures, behavioral issues, and other neurological complications if left untreated.
Neurological Consequences: The developing brain is particularly vulnerable to the toxic effects of elevated phenylalanine levels. The severity of neurological consequences can vary, but without early and ongoing treatment, individuals with PKU are at risk of significant cognitive and developmental impairments.
Etiology
Genetic Basis: The primary cause of PKU is mutations in the gene that provides instructions for making the enzyme phenylalanine hydroxylase (PAH). This gene is located on chromosome 12. PAH is essential for the normal metabolism of the amino acid phenylalanine.
Phenylalanine Hydroxylase (PAH) Gene Mutation: The PAH gene mutations result in the production of a defective or insufficient amount of the PAH enzyme. PAH is responsible for converting phenylalanine, an amino acid obtained from the diet, into another amino acid called tyrosine. Tyrosine is further metabolized to produce neurotransmitters and other essential molecules.
Autosomal Recessive Inheritance: PKU follows an autosomal recessive pattern of inheritance. This means that both parents must carry one copy of the mutated gene without showing symptoms of the disorder. When both parents are carriers, there is a 25% chance with each pregnancy that their child will inherit two copies of the mutated gene and, therefore, have PKU.
Heterozygous Carriers: Individuals who inherit one normal copy of the PAH gene and one mutated copy are carriers of the PKU gene but do not exhibit symptoms of the disorder. However, carriers can pass the mutated gene to their offspring.
Population and Ethnic Variations: The prevalence of PKU can vary among different populations and ethnic groups. Certain populations, such as individuals of European, Native American, and Turkish descent, may have a higher incidence of PKU.
Genetics
Prognostic Factors
Early Diagnosis and Treatment: Early detection through newborn screening and prompt initiation of treatment are critical prognostic factors. Newborn screening allows for the identification of PKU shortly after birth, enabling the implementation of dietary restrictions and other interventions before the development of neurological complications.
Adherence to Treatment: The prognosis of PKU is strongly influenced by the individual’s adherence to the prescribed treatment plan. This typically involves a lifelong, strict low-phenylalanine diet. Adherence to the diet helps maintain phenylalanine levels within the target range, minimizing the risk of neurological damage.
Severity of Enzyme Deficiency: The severity of PAH enzyme deficiency, resulting from specific genetic mutations, can impact the prognosis. Some individuals may have milder forms of PKU with higher residual enzyme activity, leading to less severe symptoms. Conversely, more severe enzyme deficiency may result in a greater risk of neurological complications if not properly managed.
Blood Phenylalanine Levels: Regular monitoring of blood phenylalanine levels is essential for adjusting the treatment plan. Persistent elevations in phenylalanine levels can increase the risk of intellectual disabilities and other neurological issues. Maintaining phenylalanine levels within the recommended range is crucial for optimizing outcomes.
Access to Medical Care: The availability of medical care, including access to specialists experienced in managing PKU, can impact the prognosis. Regular follow-up appointments, dietary counseling, and ongoing monitoring contribute to effective management and better outcomes.
Individual Response to Treatment: Responses to treatment can vary among individuals. Some may respond well to dietary management alone, while others may require additional interventions, such as medication. The ability to tailor treatment to individual needs can influence the long-term prognosis.
Neurological Development During Early Childhood: The impact of PKU on neurological development is most significant during early childhood. Early and effective intervention can help mitigate the risk of intellectual disabilities and other cognitive impairments.
Clinical History
Neonatal Period:
Newborn Screening: PKU is often identified through newborn screening, which is routinely performed shortly after birth. Elevated blood phenylalanine levels are detected through a heel-prick blood test.
Asymptomatic at Birth: Infants with PKU are typically asymptomatic at birth, and physical abnormalities are not immediately apparent.
Infancy and Early Childhood:
Neurological Impact: Without treatment, elevated phenylalanine levels can lead to neurological damage during the first few months of life. Symptoms may include developmental delays, microcephaly (small head size), and intellectual disabilities.
Hypopigmentation: Some infants with PKU may exhibit lighter hair, skin, and eye color due to a deficiency of melanin production.
Childhood:
Developmental Delays: Children with untreated PKU may experience ongoing developmental delays and intellectual disabilities.
Behavioral Issues: Behavioral problems, such as hyperactivity and impulsivity, may become more noticeable as children grow older.
Adolescence and Adulthood:
Cognitive Impairments: Without proper management, cognitive impairments may persist into adolescence and adulthood.
Psychiatric Symptoms: Some individuals with PKU may experience psychiatric symptoms, including anxiety and depression.
Physical Examination
Neonatal Period:
Normal Appearance: Newborns with PKU generally appear normal at birth.
Hypopigmentation: Some infants with PKU may have lighter hair, skin, and eye color due to a deficiency of melanin production.
Infancy and Early Childhood:
Developmental Delays: Children with untreated PKU may exhibit developmental delays, including delays in achieving motor and cognitive milestones.
Microcephaly: A small head size (microcephaly) may be observed.
Neurological Signs: Signs of neurological involvement, such as abnormal muscle tone or movements, may become apparent.
Childhood:
Behavioral Issues: Behavioral problems, such as hyperactivity, impulsivity, and attention difficulties, may manifest.
Dental Abnormalities: Some individuals with PKU may develop dental abnormalities, including a musty or mousy odor to the breath.
Adolescence and Adulthood:
Cognitive Impairments: Individuals with untreated PKU may continue to experience cognitive impairments, including intellectual disabilities.
Psychiatric Symptoms: Psychiatric symptoms, such as anxiety and depression, may be observed.
Age group
Associated comorbidity
Neurological Complications: Intellectual disabilities, seizures, and other neurological complications are common if PKU is not treated.
Behavioral and Psychiatric Issues: Attention deficit hyperactivity disorder (ADHD), mood disorders, and other psychiatric issues may be associated with untreated PKU.
Hypertension: There may be an increased risk of hypertension in individuals with PKU.
Associated activity
Acuity of presentation
Asymptomatic (Early): In the neonatal period, PKU is typically asymptomatic, and symptoms may not be immediately apparent without screening.
Progressive Neurological Symptoms: Without treatment, neurological symptoms can progressively manifest, leading to intellectual disabilities and behavioral issues.
Severity Varies: The severity of symptoms and the acuity of presentation can vary widely among individuals, depending on factors such as the degree of enzyme deficiency and genetic mutations.
Differential Diagnoses
Maternal Phenylketonuria (MPKU): In some cases, an infant may be exposed to high levels of phenylalanine during pregnancy if the mother has untreated or poorly managed PKU. MPKU can lead to similar neurological and developmental issues in the newborn.
Hyperphenylalaninemia (non-PKU HPA): Elevated phenylalanine levels can be caused by conditions other than PKU, such as deficiencies in the enzymes tetrahydrobiopterin (BH4) or dihydropteridine reductase. These conditions are collectively referred to as non-PKU hyperphenylalaninemias.
Biopterin Deficiencies: Disorders affecting the synthesis or recycling of tetrahydrobiopterin (BH4), a cofactor for phenylalanine hydroxylase, can lead to elevated phenylalanine levels. Conditions like BH4 deficiency or dihydropteridine reductase deficiency fall into this category.
Maple Syrup Urine Disease (MSUD): MSUD is another inherited metabolic disorder that can cause elevated levels of amino acids, including branched-chain amino acids. It may present with symptoms such as a distinctive sweet odor in the urine, vomiting, and neurological issues.
Alkaptonuria: Alkaptonuria is a rare metabolic disorder that can lead to the accumulation of homogentisic acid. While it doesn’t directly involve elevated phenylalanine levels, it can present with darkening of the urine and joint and connective tissue problems.
Hypothyroidism: Some metabolic disorders, including congenital hypothyroidism, can cause developmental delays and intellectual disabilities. Hypothyroidism is typically screened for as part of routine newborn screening.
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Dietary Management:
Low-Phenylalanine Diet: The cornerstone of PKU treatment is a strict, lifelong low-phenylalanine diet. This involves restricting the intake of high-protein foods, such as meat, fish, eggs, dairy products, and certain grains. Individuals with PKU need to consume a special medical formula that provides essential nutrients without excessive phenylalanine.
Regular Monitoring: Regular monitoring of blood phenylalanine levels is crucial. Frequent blood tests are performed to assess phenylalanine levels, allowing for adjustments to the diet to keep phenylalanine within the target range.
Dietary Adherence: Adherence to the prescribed diet is essential to prevent the accumulation of phenylalanine and the associated neurological complications. Dietitians often work closely with individuals with PKU to ensure proper nutrition and dietary compliance.
Medical Monitoring:
Regular Follow-Up: Individuals with PKU require regular follow-up appointments with a healthcare team, including a metabolic specialist, dietitian, and other relevant healthcare professionals.
Neurological and Developmental Assessments: Monitoring of developmental milestones and neurological function is crucial, especially during infancy and childhood. Early intervention can help address any emerging issues promptly.
Medications:
Sapropterin (BH4): Some individuals with PKU may respond to treatment with sapropterin dihydrochloride, a synthetic form of tetrahydrobiopterin (BH4). BH4 is a cofactor for the enzyme phenylalanine hydroxylase (PAH), and its supplementation can enhance the enzyme’s activity in certain cases.
Pegvaliase: Pegvaliase (Palynziq) is an enzyme substitution therapy that can be used in certain cases of PKU. It helps break down phenylalanine in individuals who do not respond well to dietary measures and other treatments.
Maternal PKU Management:
Preconception and Pregnancy Care: Women with PKU who are planning to become pregnant or are already pregnant require special attention. Elevated phenylalanine levels during pregnancy can lead to developmental issues in the fetus (maternal PKU syndrome). Close monitoring and adjustments to the treatment plan are essential to minimize risks.
Emerging Therapies:
Gene Therapy and Enzyme Replacement: Research is ongoing in the development of gene therapies and enzyme replacement therapies that may offer new approaches to managing PKU in the future.
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
use-of-a-non-pharmacological-approach-for-treating-phenylketonuria
The non-pharmacological approach for treating Phenylketonuria (PKU) primarily revolves around dietary management and lifestyle modifications. This approach is essential for maintaining phenylalanine levels within a safe range to prevent neurological complications. Â
Low-Phenylalanine Diet:Â
Monitoring and Adjustments:Â
Sapropterin (BH4) Supplementation:Â
Psychosocial Support:Â
Maternal PKU Management:Â
Lifestyle Modifications:Â
Use of Sapropterin (BH4) Supplementation in the treatment of Phenylketonuria
Sapropterin, also known as tetrahydrobiopterin (BH4) supplementation, is a pharmaceutical agent used in the treatment of Phenylketonuria (PKU) in specific cases. Â
Sapropterin is a synthetic form of BH4, a cofactor for the enzyme phenylalanine hydroxylase (PAH). PAH is responsible for converting phenylalanine, an amino acid found in protein-containing foods, into tyrosine. Individuals with PKU have mutations in the PAH gene, leading to reduced or absent PAH activity and elevated phenylalanine levels.Â
Sapropterin is often used as a complementary therapy to the low-phenylalanine diet. The combination of dietary management and sapropterin aims to keep phenylalanine levels within the target range and prevent neurological complications.Â
The response to sapropterin varies among individuals, and not everyone with PKU will benefit from this treatment. Genetic factors, specific mutations in the PAH gene, and other individual characteristics influence the response to BH4 supplementation.Â
Use of Pegvaliase in the treatment of Phenylketonuria
Pegvaliase, marketed under the brand name Palynziq, is an enzyme substitution therapy used in the treatment of Phenylketonuria (PKU) in specific cases. Â
Pegvaliase is a pegylated form of phenylalanine ammonia-lyase (PAL), an enzyme that converts phenylalanine (Phe) into harmless byproducts. Individuals with PKU have mutations in the phenylalanine hydroxylase (PAH) gene, leading to reduced or absent PAH activity and elevated phenylalanine levels.Â
Pegvaliase has been shown to reduce blood phenylalanine levels in some individuals with PKU effectively. Its use aims to provide an additional treatment option for those who do not respond well to dietary measures and other available therapies.Â
use-of-intervention-with-a-procedure-in-treating-phenylketonuria
The primary treatment for PKU involves a strict low-phenylalanine diet, but intervention with a specific medical procedure called enzyme replacement therapy (ERT) has also been explored in recent years.Â
Dietary Intervention:Â
Enzyme Replacement Therapy (ERT):Â
Monitoring and Individualized Care:Â
Research and Future Developments:Â
use-of-phases-in-managing-phenylketonuria
Newborn Screening:Â
Dietary Intervention:Â
Transition to Solid Foods:Â
Adolescence and Adulthood:Â
Pregnancy Planning:Â
Medical Monitoring:Â
Research and Emerging Therapies:Â
Medication
10-20 mg/kg orally daily
The levels of Blood phenylalanine (Phe) evaluated after 1 week, if Phe levels in the blood have not decreased next periodically increase dose to 20 mg/kg/day
Maintenance dose: After determining responsiveness, the dose is adjusted b/w 5 and 20 mg/kg/day according to the biochemical response.
Non-Responders:
If Phe levels would not decrease after 1 month of treatment at 20 mg/kg/day must be considered non-responders and treatment should be stopped.
Induction-2.5 mg subcutaneously weekly once for a duration of 4 weeks
Gradually adjust the dosage over a minimum of 5 weeks, following the step-wise approach
Additional time can be necessary before each dose increase depending on individual tolerance levels
Recommended titration schedule
Week first-2.5 mg twice weekly subcutaneously
Week second- Once every week, 10 mg subcutaneously
Week third-Twice weekly, 10 mg subcutaneously
Week fourth-10 mg administered subcutaneously four times every week
Week fifth- 10 mg once daily subcutaneously
Week sixth- Once daily, 20 mg subcutaneously
After a minimum duration of 24 weeks with a daily dosage of 20 mg, the possibility of raising the dosage to 40 mg per day should be considered for patients who are unable to regulate their blood phenylalanine levels
If, after a minimum duration of 16 weeks with a daily dosage of 40 mg, patients are still unable to achieve blood phenylalanine control, an increase in dosage to 60 mg per day may be considered
The dosage is 20 to 60 mg administered subcutaneously once daily
The maintenance dose should be tailored to each individual in order to achieve blood phenylalanine control, with blood phenylalanine concentrations equal to or less than 600 micromol/l
Maximum dose
If, after a minimum duration of 16 weeks with a daily dosage of 60 mg, patients do not show a satisfactory response, it is advised to discontinue the therapy
10-20 mg/kg orally daily
The levels of Blood phenylalanine (Phe) evaluated after 1 week, if Phe levels in the blood have not decreased next periodically increase dose to 20 mg/kg/day
Maintenance dose: After determining responsiveness, the dose is adjusted b/w 5 and 20 mg/kg/day according to the biochemical response.
Non-Responders:
If Phe levels would not decrease after 1 month of treatment at 20 mg/kg/day must be considered non-responders and treatment should be stopped.
Future Trends
References
Phenylketonuria:ncbi.nlm.nih
Phenylketonuria (PKU) is a rare genetic disorder affecting the metabolism of phenylalanine, an amino acid. Proteins are made up of amino acids, and phenylalanine is derived from diet—especially from foods high in protein.
It is caused by a mutation in the gene that provides instructions for making an enzyme called phenylalanine hydroxylase (PAH). This enzyme is crucial for breaking down phenylalanine into another amino acid called tyrosine. In individuals with PKU, the lack or deficiency of functional PAH leads to the accumulation of phenylalanine in the blood and body tissues.
High levels of phenylalanine can be toxic to the developing brain, especially in infants and young children. If left untreated, PKU can result in intellectual disabilities, seizures, behavioral problems, and other neurological issues.
PKU is typically diagnosed through newborn screening, which involves a blood test shortly after birth. Early detection is crucial for initiating treatment before the toxic effects of phenylalanine can cause irreversible damage.
The primary treatment for PKU involves a strict, lifelong low-phenylalanine diet. This means restricting the intake of high-protein foods, such as meat, dairy products, and certain grains. Additionally, individuals with PKU may take a special formula that provides the necessary nutrients while limiting phenylalanine. Regular monitoring of blood phenylalanine levels is essential to adjust the diet and treatment plan as needed.
Prevalence: PKU occurs worldwide but is more commonly observed in certain ethnic groups. The prevalence of PKU varies among different populations and regions. In the United States, for example, PKU occurs in about 1 in 10,000 to 15,000 births.
Genetic Inheritance: PKU is a genetic disorder that is autosomal recessive. This implies that for a child to be impacted, both parents need to have a copy of the defective gene. Every pregnancy increases the likelihood that a child of carriers will have PKU by 25%.
Ethnic Variations: The prevalence of PKU can vary among ethnic groups. It is more commonly seen in individuals of European, Native American, and Turkish descent, while it is less common in individuals of African, Hispanic, and Asian descent.
Newborn Screening: Many countries have implemented newborn screening programs to detect PKU early in life. Newborn screening involves a blood test shortly after birth to measure the levels of phenylalanine. It is essential to identify and treat neurological problems early on in order to avoid their development.
International Variances: PKU prevalence can vary significantly between countries. Some countries have established comprehensive newborn screening programs and effective treatment protocols, leading to better outcomes for individuals with PKU. In contrast, in regions with limited access to healthcare and newborn screening, cases may go undetected and untreated.
Gender Distribution: PKU affects both males and females, and there is generally no significant gender bias in its occurrence.
Genetic Mutation: Mutations in the PAH gene on chromosome 12 result in PKU, an autosomal recessive genetic disorder. Individuals with PKU inherit two mutated copies of the gene, one from each parent. These mutations result in the production of a defective or insufficient amount of PAH.
PAH Enzyme Deficiency: PAH is an enzyme responsible for converting phenylalanine into another amino acid called tyrosine. In individuals with PKU, the deficiency or absence of functional PAH leads to the impaired conversion of phenylalanine.
Accumulation of Phenylalanine: Due to the lack of PAH activity, phenylalanine accumulates in the blood and body tissues. Elevated levels of phenylalanine in the bloodstream are toxic to the developing brain, particularly in infants and young children.
Crossing the Blood-Brain Barrier: Unlike tyrosine, phenylalanine has difficulty crossing the blood-brain barrier. However, when phenylalanine levels are excessively high in the blood, it can enter the brain, leading to neurological damage.
Impact on Brain Development: The brain’s normal development and function may be hampered by phenylalanine buildup. This can result in intellectual disabilities, seizures, behavioral issues, and other neurological complications if left untreated.
Neurological Consequences: The developing brain is particularly vulnerable to the toxic effects of elevated phenylalanine levels. The severity of neurological consequences can vary, but without early and ongoing treatment, individuals with PKU are at risk of significant cognitive and developmental impairments.
Genetic Basis: The primary cause of PKU is mutations in the gene that provides instructions for making the enzyme phenylalanine hydroxylase (PAH). This gene is located on chromosome 12. PAH is essential for the normal metabolism of the amino acid phenylalanine.
Phenylalanine Hydroxylase (PAH) Gene Mutation: The PAH gene mutations result in the production of a defective or insufficient amount of the PAH enzyme. PAH is responsible for converting phenylalanine, an amino acid obtained from the diet, into another amino acid called tyrosine. Tyrosine is further metabolized to produce neurotransmitters and other essential molecules.
Autosomal Recessive Inheritance: PKU follows an autosomal recessive pattern of inheritance. This means that both parents must carry one copy of the mutated gene without showing symptoms of the disorder. When both parents are carriers, there is a 25% chance with each pregnancy that their child will inherit two copies of the mutated gene and, therefore, have PKU.
Heterozygous Carriers: Individuals who inherit one normal copy of the PAH gene and one mutated copy are carriers of the PKU gene but do not exhibit symptoms of the disorder. However, carriers can pass the mutated gene to their offspring.
Population and Ethnic Variations: The prevalence of PKU can vary among different populations and ethnic groups. Certain populations, such as individuals of European, Native American, and Turkish descent, may have a higher incidence of PKU.
Early Diagnosis and Treatment: Early detection through newborn screening and prompt initiation of treatment are critical prognostic factors. Newborn screening allows for the identification of PKU shortly after birth, enabling the implementation of dietary restrictions and other interventions before the development of neurological complications.
Adherence to Treatment: The prognosis of PKU is strongly influenced by the individual’s adherence to the prescribed treatment plan. This typically involves a lifelong, strict low-phenylalanine diet. Adherence to the diet helps maintain phenylalanine levels within the target range, minimizing the risk of neurological damage.
Severity of Enzyme Deficiency: The severity of PAH enzyme deficiency, resulting from specific genetic mutations, can impact the prognosis. Some individuals may have milder forms of PKU with higher residual enzyme activity, leading to less severe symptoms. Conversely, more severe enzyme deficiency may result in a greater risk of neurological complications if not properly managed.
Blood Phenylalanine Levels: Regular monitoring of blood phenylalanine levels is essential for adjusting the treatment plan. Persistent elevations in phenylalanine levels can increase the risk of intellectual disabilities and other neurological issues. Maintaining phenylalanine levels within the recommended range is crucial for optimizing outcomes.
Access to Medical Care: The availability of medical care, including access to specialists experienced in managing PKU, can impact the prognosis. Regular follow-up appointments, dietary counseling, and ongoing monitoring contribute to effective management and better outcomes.
Individual Response to Treatment: Responses to treatment can vary among individuals. Some may respond well to dietary management alone, while others may require additional interventions, such as medication. The ability to tailor treatment to individual needs can influence the long-term prognosis.
Neurological Development During Early Childhood: The impact of PKU on neurological development is most significant during early childhood. Early and effective intervention can help mitigate the risk of intellectual disabilities and other cognitive impairments.
Neonatal Period:
Newborn Screening: PKU is often identified through newborn screening, which is routinely performed shortly after birth. Elevated blood phenylalanine levels are detected through a heel-prick blood test.
Asymptomatic at Birth: Infants with PKU are typically asymptomatic at birth, and physical abnormalities are not immediately apparent.
Infancy and Early Childhood:
Neurological Impact: Without treatment, elevated phenylalanine levels can lead to neurological damage during the first few months of life. Symptoms may include developmental delays, microcephaly (small head size), and intellectual disabilities.
Hypopigmentation: Some infants with PKU may exhibit lighter hair, skin, and eye color due to a deficiency of melanin production.
Childhood:
Developmental Delays: Children with untreated PKU may experience ongoing developmental delays and intellectual disabilities.
Behavioral Issues: Behavioral problems, such as hyperactivity and impulsivity, may become more noticeable as children grow older.
Adolescence and Adulthood:
Cognitive Impairments: Without proper management, cognitive impairments may persist into adolescence and adulthood.
Psychiatric Symptoms: Some individuals with PKU may experience psychiatric symptoms, including anxiety and depression.
Neonatal Period:
Normal Appearance: Newborns with PKU generally appear normal at birth.
Hypopigmentation: Some infants with PKU may have lighter hair, skin, and eye color due to a deficiency of melanin production.
Infancy and Early Childhood:
Developmental Delays: Children with untreated PKU may exhibit developmental delays, including delays in achieving motor and cognitive milestones.
Microcephaly: A small head size (microcephaly) may be observed.
Neurological Signs: Signs of neurological involvement, such as abnormal muscle tone or movements, may become apparent.
Childhood:
Behavioral Issues: Behavioral problems, such as hyperactivity, impulsivity, and attention difficulties, may manifest.
Dental Abnormalities: Some individuals with PKU may develop dental abnormalities, including a musty or mousy odor to the breath.
Adolescence and Adulthood:
Cognitive Impairments: Individuals with untreated PKU may continue to experience cognitive impairments, including intellectual disabilities.
Psychiatric Symptoms: Psychiatric symptoms, such as anxiety and depression, may be observed.
Neurological Complications: Intellectual disabilities, seizures, and other neurological complications are common if PKU is not treated.
Behavioral and Psychiatric Issues: Attention deficit hyperactivity disorder (ADHD), mood disorders, and other psychiatric issues may be associated with untreated PKU.
Hypertension: There may be an increased risk of hypertension in individuals with PKU.
Asymptomatic (Early): In the neonatal period, PKU is typically asymptomatic, and symptoms may not be immediately apparent without screening.
Progressive Neurological Symptoms: Without treatment, neurological symptoms can progressively manifest, leading to intellectual disabilities and behavioral issues.
Severity Varies: The severity of symptoms and the acuity of presentation can vary widely among individuals, depending on factors such as the degree of enzyme deficiency and genetic mutations.
Maternal Phenylketonuria (MPKU): In some cases, an infant may be exposed to high levels of phenylalanine during pregnancy if the mother has untreated or poorly managed PKU. MPKU can lead to similar neurological and developmental issues in the newborn.
Hyperphenylalaninemia (non-PKU HPA): Elevated phenylalanine levels can be caused by conditions other than PKU, such as deficiencies in the enzymes tetrahydrobiopterin (BH4) or dihydropteridine reductase. These conditions are collectively referred to as non-PKU hyperphenylalaninemias.
Biopterin Deficiencies: Disorders affecting the synthesis or recycling of tetrahydrobiopterin (BH4), a cofactor for phenylalanine hydroxylase, can lead to elevated phenylalanine levels. Conditions like BH4 deficiency or dihydropteridine reductase deficiency fall into this category.
Maple Syrup Urine Disease (MSUD): MSUD is another inherited metabolic disorder that can cause elevated levels of amino acids, including branched-chain amino acids. It may present with symptoms such as a distinctive sweet odor in the urine, vomiting, and neurological issues.
Alkaptonuria: Alkaptonuria is a rare metabolic disorder that can lead to the accumulation of homogentisic acid. While it doesn’t directly involve elevated phenylalanine levels, it can present with darkening of the urine and joint and connective tissue problems.
Hypothyroidism: Some metabolic disorders, including congenital hypothyroidism, can cause developmental delays and intellectual disabilities. Hypothyroidism is typically screened for as part of routine newborn screening.
Dietary Management:
Low-Phenylalanine Diet: The cornerstone of PKU treatment is a strict, lifelong low-phenylalanine diet. This involves restricting the intake of high-protein foods, such as meat, fish, eggs, dairy products, and certain grains. Individuals with PKU need to consume a special medical formula that provides essential nutrients without excessive phenylalanine.
Regular Monitoring: Regular monitoring of blood phenylalanine levels is crucial. Frequent blood tests are performed to assess phenylalanine levels, allowing for adjustments to the diet to keep phenylalanine within the target range.
Dietary Adherence: Adherence to the prescribed diet is essential to prevent the accumulation of phenylalanine and the associated neurological complications. Dietitians often work closely with individuals with PKU to ensure proper nutrition and dietary compliance.
Medical Monitoring:
Regular Follow-Up: Individuals with PKU require regular follow-up appointments with a healthcare team, including a metabolic specialist, dietitian, and other relevant healthcare professionals.
Neurological and Developmental Assessments: Monitoring of developmental milestones and neurological function is crucial, especially during infancy and childhood. Early intervention can help address any emerging issues promptly.
Medications:
Sapropterin (BH4): Some individuals with PKU may respond to treatment with sapropterin dihydrochloride, a synthetic form of tetrahydrobiopterin (BH4). BH4 is a cofactor for the enzyme phenylalanine hydroxylase (PAH), and its supplementation can enhance the enzyme’s activity in certain cases.
Pegvaliase: Pegvaliase (Palynziq) is an enzyme substitution therapy that can be used in certain cases of PKU. It helps break down phenylalanine in individuals who do not respond well to dietary measures and other treatments.
Maternal PKU Management:
Preconception and Pregnancy Care: Women with PKU who are planning to become pregnant or are already pregnant require special attention. Elevated phenylalanine levels during pregnancy can lead to developmental issues in the fetus (maternal PKU syndrome). Close monitoring and adjustments to the treatment plan are essential to minimize risks.
Emerging Therapies:
Gene Therapy and Enzyme Replacement: Research is ongoing in the development of gene therapies and enzyme replacement therapies that may offer new approaches to managing PKU in the future.
Psychiatry/Mental Health
The non-pharmacological approach for treating Phenylketonuria (PKU) primarily revolves around dietary management and lifestyle modifications. This approach is essential for maintaining phenylalanine levels within a safe range to prevent neurological complications. Â
Low-Phenylalanine Diet:Â
Monitoring and Adjustments:Â
Sapropterin (BH4) Supplementation:Â
Psychosocial Support:Â
Maternal PKU Management:Â
Lifestyle Modifications:Â
Neurology
Sapropterin, also known as tetrahydrobiopterin (BH4) supplementation, is a pharmaceutical agent used in the treatment of Phenylketonuria (PKU) in specific cases. Â
Sapropterin is a synthetic form of BH4, a cofactor for the enzyme phenylalanine hydroxylase (PAH). PAH is responsible for converting phenylalanine, an amino acid found in protein-containing foods, into tyrosine. Individuals with PKU have mutations in the PAH gene, leading to reduced or absent PAH activity and elevated phenylalanine levels.Â
Sapropterin is often used as a complementary therapy to the low-phenylalanine diet. The combination of dietary management and sapropterin aims to keep phenylalanine levels within the target range and prevent neurological complications.Â
The response to sapropterin varies among individuals, and not everyone with PKU will benefit from this treatment. Genetic factors, specific mutations in the PAH gene, and other individual characteristics influence the response to BH4 supplementation.Â
Neurology
Pegvaliase, marketed under the brand name Palynziq, is an enzyme substitution therapy used in the treatment of Phenylketonuria (PKU) in specific cases. Â
Pegvaliase is a pegylated form of phenylalanine ammonia-lyase (PAL), an enzyme that converts phenylalanine (Phe) into harmless byproducts. Individuals with PKU have mutations in the phenylalanine hydroxylase (PAH) gene, leading to reduced or absent PAH activity and elevated phenylalanine levels.Â
Pegvaliase has been shown to reduce blood phenylalanine levels in some individuals with PKU effectively. Its use aims to provide an additional treatment option for those who do not respond well to dietary measures and other available therapies.Â
Neurology
The primary treatment for PKU involves a strict low-phenylalanine diet, but intervention with a specific medical procedure called enzyme replacement therapy (ERT) has also been explored in recent years.Â
Dietary Intervention:Â
Enzyme Replacement Therapy (ERT):Â
Monitoring and Individualized Care:Â
Research and Future Developments:Â
Neurology
Newborn Screening:Â
Dietary Intervention:Â
Transition to Solid Foods:Â
Adolescence and Adulthood:Â
Pregnancy Planning:Â
Medical Monitoring:Â
Research and Emerging Therapies:Â
Phenylketonuria:ncbi.nlm.nih
Phenylketonuria (PKU) is a rare genetic disorder affecting the metabolism of phenylalanine, an amino acid. Proteins are made up of amino acids, and phenylalanine is derived from diet—especially from foods high in protein.
It is caused by a mutation in the gene that provides instructions for making an enzyme called phenylalanine hydroxylase (PAH). This enzyme is crucial for breaking down phenylalanine into another amino acid called tyrosine. In individuals with PKU, the lack or deficiency of functional PAH leads to the accumulation of phenylalanine in the blood and body tissues.
High levels of phenylalanine can be toxic to the developing brain, especially in infants and young children. If left untreated, PKU can result in intellectual disabilities, seizures, behavioral problems, and other neurological issues.
PKU is typically diagnosed through newborn screening, which involves a blood test shortly after birth. Early detection is crucial for initiating treatment before the toxic effects of phenylalanine can cause irreversible damage.
The primary treatment for PKU involves a strict, lifelong low-phenylalanine diet. This means restricting the intake of high-protein foods, such as meat, dairy products, and certain grains. Additionally, individuals with PKU may take a special formula that provides the necessary nutrients while limiting phenylalanine. Regular monitoring of blood phenylalanine levels is essential to adjust the diet and treatment plan as needed.
Prevalence: PKU occurs worldwide but is more commonly observed in certain ethnic groups. The prevalence of PKU varies among different populations and regions. In the United States, for example, PKU occurs in about 1 in 10,000 to 15,000 births.
Genetic Inheritance: PKU is a genetic disorder that is autosomal recessive. This implies that for a child to be impacted, both parents need to have a copy of the defective gene. Every pregnancy increases the likelihood that a child of carriers will have PKU by 25%.
Ethnic Variations: The prevalence of PKU can vary among ethnic groups. It is more commonly seen in individuals of European, Native American, and Turkish descent, while it is less common in individuals of African, Hispanic, and Asian descent.
Newborn Screening: Many countries have implemented newborn screening programs to detect PKU early in life. Newborn screening involves a blood test shortly after birth to measure the levels of phenylalanine. It is essential to identify and treat neurological problems early on in order to avoid their development.
International Variances: PKU prevalence can vary significantly between countries. Some countries have established comprehensive newborn screening programs and effective treatment protocols, leading to better outcomes for individuals with PKU. In contrast, in regions with limited access to healthcare and newborn screening, cases may go undetected and untreated.
Gender Distribution: PKU affects both males and females, and there is generally no significant gender bias in its occurrence.
Genetic Mutation: Mutations in the PAH gene on chromosome 12 result in PKU, an autosomal recessive genetic disorder. Individuals with PKU inherit two mutated copies of the gene, one from each parent. These mutations result in the production of a defective or insufficient amount of PAH.
PAH Enzyme Deficiency: PAH is an enzyme responsible for converting phenylalanine into another amino acid called tyrosine. In individuals with PKU, the deficiency or absence of functional PAH leads to the impaired conversion of phenylalanine.
Accumulation of Phenylalanine: Due to the lack of PAH activity, phenylalanine accumulates in the blood and body tissues. Elevated levels of phenylalanine in the bloodstream are toxic to the developing brain, particularly in infants and young children.
Crossing the Blood-Brain Barrier: Unlike tyrosine, phenylalanine has difficulty crossing the blood-brain barrier. However, when phenylalanine levels are excessively high in the blood, it can enter the brain, leading to neurological damage.
Impact on Brain Development: The brain’s normal development and function may be hampered by phenylalanine buildup. This can result in intellectual disabilities, seizures, behavioral issues, and other neurological complications if left untreated.
Neurological Consequences: The developing brain is particularly vulnerable to the toxic effects of elevated phenylalanine levels. The severity of neurological consequences can vary, but without early and ongoing treatment, individuals with PKU are at risk of significant cognitive and developmental impairments.
Genetic Basis: The primary cause of PKU is mutations in the gene that provides instructions for making the enzyme phenylalanine hydroxylase (PAH). This gene is located on chromosome 12. PAH is essential for the normal metabolism of the amino acid phenylalanine.
Phenylalanine Hydroxylase (PAH) Gene Mutation: The PAH gene mutations result in the production of a defective or insufficient amount of the PAH enzyme. PAH is responsible for converting phenylalanine, an amino acid obtained from the diet, into another amino acid called tyrosine. Tyrosine is further metabolized to produce neurotransmitters and other essential molecules.
Autosomal Recessive Inheritance: PKU follows an autosomal recessive pattern of inheritance. This means that both parents must carry one copy of the mutated gene without showing symptoms of the disorder. When both parents are carriers, there is a 25% chance with each pregnancy that their child will inherit two copies of the mutated gene and, therefore, have PKU.
Heterozygous Carriers: Individuals who inherit one normal copy of the PAH gene and one mutated copy are carriers of the PKU gene but do not exhibit symptoms of the disorder. However, carriers can pass the mutated gene to their offspring.
Population and Ethnic Variations: The prevalence of PKU can vary among different populations and ethnic groups. Certain populations, such as individuals of European, Native American, and Turkish descent, may have a higher incidence of PKU.
Early Diagnosis and Treatment: Early detection through newborn screening and prompt initiation of treatment are critical prognostic factors. Newborn screening allows for the identification of PKU shortly after birth, enabling the implementation of dietary restrictions and other interventions before the development of neurological complications.
Adherence to Treatment: The prognosis of PKU is strongly influenced by the individual’s adherence to the prescribed treatment plan. This typically involves a lifelong, strict low-phenylalanine diet. Adherence to the diet helps maintain phenylalanine levels within the target range, minimizing the risk of neurological damage.
Severity of Enzyme Deficiency: The severity of PAH enzyme deficiency, resulting from specific genetic mutations, can impact the prognosis. Some individuals may have milder forms of PKU with higher residual enzyme activity, leading to less severe symptoms. Conversely, more severe enzyme deficiency may result in a greater risk of neurological complications if not properly managed.
Blood Phenylalanine Levels: Regular monitoring of blood phenylalanine levels is essential for adjusting the treatment plan. Persistent elevations in phenylalanine levels can increase the risk of intellectual disabilities and other neurological issues. Maintaining phenylalanine levels within the recommended range is crucial for optimizing outcomes.
Access to Medical Care: The availability of medical care, including access to specialists experienced in managing PKU, can impact the prognosis. Regular follow-up appointments, dietary counseling, and ongoing monitoring contribute to effective management and better outcomes.
Individual Response to Treatment: Responses to treatment can vary among individuals. Some may respond well to dietary management alone, while others may require additional interventions, such as medication. The ability to tailor treatment to individual needs can influence the long-term prognosis.
Neurological Development During Early Childhood: The impact of PKU on neurological development is most significant during early childhood. Early and effective intervention can help mitigate the risk of intellectual disabilities and other cognitive impairments.
Neonatal Period:
Newborn Screening: PKU is often identified through newborn screening, which is routinely performed shortly after birth. Elevated blood phenylalanine levels are detected through a heel-prick blood test.
Asymptomatic at Birth: Infants with PKU are typically asymptomatic at birth, and physical abnormalities are not immediately apparent.
Infancy and Early Childhood:
Neurological Impact: Without treatment, elevated phenylalanine levels can lead to neurological damage during the first few months of life. Symptoms may include developmental delays, microcephaly (small head size), and intellectual disabilities.
Hypopigmentation: Some infants with PKU may exhibit lighter hair, skin, and eye color due to a deficiency of melanin production.
Childhood:
Developmental Delays: Children with untreated PKU may experience ongoing developmental delays and intellectual disabilities.
Behavioral Issues: Behavioral problems, such as hyperactivity and impulsivity, may become more noticeable as children grow older.
Adolescence and Adulthood:
Cognitive Impairments: Without proper management, cognitive impairments may persist into adolescence and adulthood.
Psychiatric Symptoms: Some individuals with PKU may experience psychiatric symptoms, including anxiety and depression.
Neonatal Period:
Normal Appearance: Newborns with PKU generally appear normal at birth.
Hypopigmentation: Some infants with PKU may have lighter hair, skin, and eye color due to a deficiency of melanin production.
Infancy and Early Childhood:
Developmental Delays: Children with untreated PKU may exhibit developmental delays, including delays in achieving motor and cognitive milestones.
Microcephaly: A small head size (microcephaly) may be observed.
Neurological Signs: Signs of neurological involvement, such as abnormal muscle tone or movements, may become apparent.
Childhood:
Behavioral Issues: Behavioral problems, such as hyperactivity, impulsivity, and attention difficulties, may manifest.
Dental Abnormalities: Some individuals with PKU may develop dental abnormalities, including a musty or mousy odor to the breath.
Adolescence and Adulthood:
Cognitive Impairments: Individuals with untreated PKU may continue to experience cognitive impairments, including intellectual disabilities.
Psychiatric Symptoms: Psychiatric symptoms, such as anxiety and depression, may be observed.
Neurological Complications: Intellectual disabilities, seizures, and other neurological complications are common if PKU is not treated.
Behavioral and Psychiatric Issues: Attention deficit hyperactivity disorder (ADHD), mood disorders, and other psychiatric issues may be associated with untreated PKU.
Hypertension: There may be an increased risk of hypertension in individuals with PKU.
Asymptomatic (Early): In the neonatal period, PKU is typically asymptomatic, and symptoms may not be immediately apparent without screening.
Progressive Neurological Symptoms: Without treatment, neurological symptoms can progressively manifest, leading to intellectual disabilities and behavioral issues.
Severity Varies: The severity of symptoms and the acuity of presentation can vary widely among individuals, depending on factors such as the degree of enzyme deficiency and genetic mutations.
Maternal Phenylketonuria (MPKU): In some cases, an infant may be exposed to high levels of phenylalanine during pregnancy if the mother has untreated or poorly managed PKU. MPKU can lead to similar neurological and developmental issues in the newborn.
Hyperphenylalaninemia (non-PKU HPA): Elevated phenylalanine levels can be caused by conditions other than PKU, such as deficiencies in the enzymes tetrahydrobiopterin (BH4) or dihydropteridine reductase. These conditions are collectively referred to as non-PKU hyperphenylalaninemias.
Biopterin Deficiencies: Disorders affecting the synthesis or recycling of tetrahydrobiopterin (BH4), a cofactor for phenylalanine hydroxylase, can lead to elevated phenylalanine levels. Conditions like BH4 deficiency or dihydropteridine reductase deficiency fall into this category.
Maple Syrup Urine Disease (MSUD): MSUD is another inherited metabolic disorder that can cause elevated levels of amino acids, including branched-chain amino acids. It may present with symptoms such as a distinctive sweet odor in the urine, vomiting, and neurological issues.
Alkaptonuria: Alkaptonuria is a rare metabolic disorder that can lead to the accumulation of homogentisic acid. While it doesn’t directly involve elevated phenylalanine levels, it can present with darkening of the urine and joint and connective tissue problems.
Hypothyroidism: Some metabolic disorders, including congenital hypothyroidism, can cause developmental delays and intellectual disabilities. Hypothyroidism is typically screened for as part of routine newborn screening.
Dietary Management:
Low-Phenylalanine Diet: The cornerstone of PKU treatment is a strict, lifelong low-phenylalanine diet. This involves restricting the intake of high-protein foods, such as meat, fish, eggs, dairy products, and certain grains. Individuals with PKU need to consume a special medical formula that provides essential nutrients without excessive phenylalanine.
Regular Monitoring: Regular monitoring of blood phenylalanine levels is crucial. Frequent blood tests are performed to assess phenylalanine levels, allowing for adjustments to the diet to keep phenylalanine within the target range.
Dietary Adherence: Adherence to the prescribed diet is essential to prevent the accumulation of phenylalanine and the associated neurological complications. Dietitians often work closely with individuals with PKU to ensure proper nutrition and dietary compliance.
Medical Monitoring:
Regular Follow-Up: Individuals with PKU require regular follow-up appointments with a healthcare team, including a metabolic specialist, dietitian, and other relevant healthcare professionals.
Neurological and Developmental Assessments: Monitoring of developmental milestones and neurological function is crucial, especially during infancy and childhood. Early intervention can help address any emerging issues promptly.
Medications:
Sapropterin (BH4): Some individuals with PKU may respond to treatment with sapropterin dihydrochloride, a synthetic form of tetrahydrobiopterin (BH4). BH4 is a cofactor for the enzyme phenylalanine hydroxylase (PAH), and its supplementation can enhance the enzyme’s activity in certain cases.
Pegvaliase: Pegvaliase (Palynziq) is an enzyme substitution therapy that can be used in certain cases of PKU. It helps break down phenylalanine in individuals who do not respond well to dietary measures and other treatments.
Maternal PKU Management:
Preconception and Pregnancy Care: Women with PKU who are planning to become pregnant or are already pregnant require special attention. Elevated phenylalanine levels during pregnancy can lead to developmental issues in the fetus (maternal PKU syndrome). Close monitoring and adjustments to the treatment plan are essential to minimize risks.
Emerging Therapies:
Gene Therapy and Enzyme Replacement: Research is ongoing in the development of gene therapies and enzyme replacement therapies that may offer new approaches to managing PKU in the future.
Psychiatry/Mental Health
The non-pharmacological approach for treating Phenylketonuria (PKU) primarily revolves around dietary management and lifestyle modifications. This approach is essential for maintaining phenylalanine levels within a safe range to prevent neurological complications. Â
Low-Phenylalanine Diet:Â
Monitoring and Adjustments:Â
Sapropterin (BH4) Supplementation:Â
Psychosocial Support:Â
Maternal PKU Management:Â
Lifestyle Modifications:Â
Neurology
Sapropterin, also known as tetrahydrobiopterin (BH4) supplementation, is a pharmaceutical agent used in the treatment of Phenylketonuria (PKU) in specific cases. Â
Sapropterin is a synthetic form of BH4, a cofactor for the enzyme phenylalanine hydroxylase (PAH). PAH is responsible for converting phenylalanine, an amino acid found in protein-containing foods, into tyrosine. Individuals with PKU have mutations in the PAH gene, leading to reduced or absent PAH activity and elevated phenylalanine levels.Â
Sapropterin is often used as a complementary therapy to the low-phenylalanine diet. The combination of dietary management and sapropterin aims to keep phenylalanine levels within the target range and prevent neurological complications.Â
The response to sapropterin varies among individuals, and not everyone with PKU will benefit from this treatment. Genetic factors, specific mutations in the PAH gene, and other individual characteristics influence the response to BH4 supplementation.Â
Neurology
Pegvaliase, marketed under the brand name Palynziq, is an enzyme substitution therapy used in the treatment of Phenylketonuria (PKU) in specific cases. Â
Pegvaliase is a pegylated form of phenylalanine ammonia-lyase (PAL), an enzyme that converts phenylalanine (Phe) into harmless byproducts. Individuals with PKU have mutations in the phenylalanine hydroxylase (PAH) gene, leading to reduced or absent PAH activity and elevated phenylalanine levels.Â
Pegvaliase has been shown to reduce blood phenylalanine levels in some individuals with PKU effectively. Its use aims to provide an additional treatment option for those who do not respond well to dietary measures and other available therapies.Â
Neurology
The primary treatment for PKU involves a strict low-phenylalanine diet, but intervention with a specific medical procedure called enzyme replacement therapy (ERT) has also been explored in recent years.Â
Dietary Intervention:Â
Enzyme Replacement Therapy (ERT):Â
Monitoring and Individualized Care:Â
Research and Future Developments:Â
Neurology
Newborn Screening:Â
Dietary Intervention:Â
Transition to Solid Foods:Â
Adolescence and Adulthood:Â
Pregnancy Planning:Â
Medical Monitoring:Â
Research and Emerging Therapies:Â
Phenylketonuria:ncbi.nlm.nih
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
